Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. reports news as a contract research organization providing nonclinical and analytical drug discovery and development services, research models, and related products for pharmaceutical, chemical, medical device, and biomedical research customers. Its updates commonly address Discovery and Safety Assessment activity, Research Models and Services performance, quarterly and annual financial results, and business trends tied to discovery, preclinical, and translational research demand.
Company announcements also cover collaborations and technology additions such as human-relevant in vitro models, AI-assisted bioinformatics, and multi-omics analysis within Discovery & Translational Sciences. Other recurring items include conference-call schedules, operational business updates, cybersecurity incident notices, and corporate communications affecting Nasdaq-listed common stock.
Inotiv, Inc. (NASDAQ:NOTV) has signed a merger agreement with Bolder BioPATH, a company specializing in pharmacology and pathology services. This acquisition is valued at $47 million, involving $18.5 million in cash and shares. Bolder BioPATH reported $13 million in revenue for 2020 and has experienced over 20% annual growth prior to the pandemic. The merger will enhance Inotiv's capabilities in drug discovery and provide cross-selling opportunities, while all existing Bolder BioPATH employees are expected to be retained post-transaction, which is anticipated to close within 120 days.
Inotiv, Inc. (NASDAQ:NOTV) announced its agreement to acquire HistoTox Labs, Inc. for $22 million in cash. HistoTox Labs, specializing in histopathology services, generated revenues of $9.1 million in 2020, with a strong growth rate exceeding 30% over the past three years. This acquisition aims to enhance Inotiv’s service offerings, particularly in cell and gene therapy, leveraging HistoTox Labs' advanced capabilities and employee expertise. The transaction is expected to close within 120 days, pending financing and customary closing conditions.
Inotiv (NASDAQ:NOTV) has partnered with PhoenixBio Co., Ltd. to enhance research services at its U.S. labs using the proprietary PXB-mouse® model. This collaboration is set to advance translational research for hepatic diseases and gene therapies, leveraging Inotiv's expertise with liver-humanized models.
Kelly Long, Inotiv's Senior Director, emphasized the importance of this partnership in providing advanced evaluation methods for new therapies. The PXB-mouse® is widely used for drug metabolism and pharmacokinetics, indicating a robust demand for its applications.